SCHEMBL699241

SCHEMBL699241

Cc1cc(=O)n(-c2cc(C(=O)O)cc(S(=O)(=O)O)c2)[nH]1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.59
MAPT P10636 4/20 0.59
KDM4E B2RXH2 3/20 0.59
KMT2A Q03164 2/20 0.59
SMN1; SMN2 Q16637 2/20 0.59
TDP1 Q9NUW8 1/20 0.59
LCK P06239 1/20 0.54
FYN P06241 1/20 0.54
KDM5A P29375 1/20 0.47
KDM2B Q8NHM5 1/20 0.47
KDM4C Q9H3R0 1/20 0.47
GAA P10253 2/20 0.46
HTT P42858 2/20 0.46
MEN1 O00255 1/20 0.46
ALKBH5 Q6P6C2 11/20 0.41
LMNA P02545 1/20 0.40
RECQL P46063 1/20 0.40
NR4A1 P22736 1/20 0.39
CYP1A2 P05177 1/20 0.36
ENPP3 O14638 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10607599 0.87 MAPT (0.54) ALDH1A1MAPTKDM4EKMT2ASMN1; SMN2
SCHEMBL10654204 0.79 ALDH1A1 (0.60) ALDH1A1MAPTKDM4EKMT2ASMN1; SMN2
SCHEMBL1265785 0.79 ALKBH5 (0.55) ALDH1A1MAPTKDM4EKMT2ASMN1; SMN2
SCHEMBL395368 0.77 ALDH1A1 (0.66) ALDH1A1MAPTKDM4EKMT2ASMN1; SMN2
SCHEMBL393039 0.76 ALDH1A1 (0.53) ALDH1A1MAPTKDM4EKMT2ASMN1; SMN2
SCHEMBL10698670 0.76 ALDH1A1 (0.53) ALDH1A1MAPTKDM4EKMT2ASMN1; SMN2
SCHEMBL10608289 0.76 ALDH1A1 (0.46) ALDH1A1MAPTKDM4EKMT2ASMN1; SMN2
SCHEMBL144358 0.75 LCK (0.95) ALDH1A1MAPTKDM4ESMN1; SMN2TDP1
SCHEMBL10834947 0.75 LCK (0.95) ALDH1A1MAPTKDM4ESMN1; SMN2TDP1
SCHEMBL940282 0.75 LCK (0.95) ALDH1A1MAPTKDM4ESMN1; SMN2TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2421613-A2 KERATIN DYEING COMPOSITIONS COMPRISING A RADICAL SCAVENGER AND A CHELANT AND USE THEREOF The Procter & Gamble Company (US) 2012-02-29 EP claimed
US-7985266-B2 Keratin dyeing compositions comprising a radical scavenger and a chelant and use thereof THE PROCTER & GAMBLE COMPANY (US) 2011-07-26 US claimed
US-20110035886-A1 Keratin Dyeing Compositions Comprising a Radical Scavenger and a Chelant and Use Thereof NOXELL CORPORATION 2011-02-17 US claimed
WO-2010123866-A2 KERATIN DYEING COMPOSITIONS COMPRISING A RADICAL SCAVENGER AND A CHELANT AND USE THEREOF THE PROCTER & GAMBLE COMPANY (US) 2010-10-28 WO claimed
EP-2421613-A2 KERATIN DYEING COMPOSITIONS COMPRISING A RADICAL SCAVENGER AND A CHELANT AND USE THEREOF The Procter & Gamble Company (US) 2012-02-29 EP disclosed
US-7985266-B2 Keratin dyeing compositions comprising a radical scavenger and a chelant and use thereof THE PROCTER & GAMBLE COMPANY (US) 2011-07-26 US disclosed
US-20110035886-A1 Keratin Dyeing Compositions Comprising a Radical Scavenger and a Chelant and Use Thereof NOXELL CORPORATION 2011-02-17 US disclosed
WO-2010123866-A2 KERATIN DYEING COMPOSITIONS COMPRISING A RADICAL SCAVENGER AND A CHELANT AND USE THEREOF THE PROCTER & GAMBLE COMPANY (US) 2010-10-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110035886-A1 Keratin Dyeing Compositions Comprising a Radical Scavenger and a Chelant and Use Thereof KRT18, LPO, KRTCAP2 ALDH1A1 354/4885MAPT 547/4885KDM4E 509/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.